IN-VIVO METABOLISM AND DISPOSITION OF A NEW ANTICANCER PARP INHIBITOR BMN 673 IN RAT AND DOG

被引：0
|
作者：
Musson, Donald
Musson, Donald G.
Haroldsen, Peter
Oppeneer, Todd
Bashir, Mohammed
O'Neill, Charles
机构：
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：126 / 127
页数：2
相关论文
共 50 条
  • [1] Discovery and preclinical characterization of BMN 673, a highly potent and orally active PARP inhibitor as an anticancer agent
    Wang, Bing
    Chu, Daniel
    Shen, Yuqiao
    Feng, Ying
    Myers, Peter
    Post, Leonard
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [2] Selective sensitivity of Ewing's Sarcoma to the PARP inhibitor BMN 673
    Singh, Arun
    Chmielowski, Bartosz
    Jia, Weiping
    Clarke, Kareem
    O'Brien, Neil
    Dering, Judy
    Conklin, Dylan
    Shen, Yuqiao
    Post, Leonard
    Finn, Richard S.
    Slamon, Dennis J.
    CANCER RESEARCH, 2013, 73 (08)
  • [3] Population Pharmacokinetics of BMN 673, a Novel PARP Inhibitor, in Beagle Dogs
    Qi, Yulan
    Musson, Don
    Tsuruda, Laurie
    Zhou, Huiyu
    Cheng, Alphonsus
    O'Neill, Charles
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S30 - S30
  • [4] PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
    Herriott, Ashleigh
    Tudhope, Susan J.
    Junge, Gesa
    Rodrigues, Natalie
    Patterson, Miranda J.
    Woodhouse, Laura
    Lunec, John
    Hunter, Jill E.
    Mulligan, Evan A.
    Cole, Michael
    Allinson, Lisa M.
    Wallis, Jonathan P.
    Marshall, Scott
    Wang, Evelyn
    Curtin, Nicola J.
    Willmore, Elaine
    ONCOTARGET, 2015, 6 (41) : 43978 - 43991
  • [5] Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional In Vivo Response to BMN 673
    Smith, Malcolm A.
    Hampton, Oliver A.
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Wu, Jianrong
    Kurmasheva, Raushan T.
    Wheeler, David A.
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (01) : 91 - 98
  • [6] BMN-673 Poly [ADP-ribose] Polymerase (PARP) Inhibitor Oncolytic
    Gras, Jordi
    DRUGS OF THE FUTURE, 2013, 38 (12) : 813 - 819
  • [7] BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
    Soni, Aashish
    Lin, Xixi
    Mladenov, Emil
    Mladenova, Veronika
    Stuschke, Martin
    Iliakis, George
    CANCERS, 2022, 14 (22)
  • [8] Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors
    Henshaw, Joshua W.
    Zhou, Huiyu
    Herriott, Ashleigh
    Patterson, Miranda
    Wang, Evelyn W.
    Musson, Don
    de Bono, Johann
    Mina, Lida A.
    Ramanathan, Ramesh K.
    O'Neill, Charles
    Dorr, Andrew
    Curtin, Nicola J.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [9] Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
    Wilkerson, Paul M.
    Dedes, Konstantin J.
    Samartzis, Eleftherios Pierre
    Dedes, Ioannis
    Lambros, Maryou B.
    Natrajan, Rachael
    Gauthier, Arnaud
    Piscuoglio, Salvatore
    Topfer, Chantal
    Vukovic, Vesna
    Daley, Frances
    Weigelt, Britta
    Reis-Filho, Jorge S.
    ONCOTARGET, 2017, 8 (04) : 6057 - 6066
  • [10] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile
    Eskiler, Gamze Guney
    Cecener, Gulsah
    Egeli, Unal
    Tunca, Berrin
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2019, 33 (05)
12345